1101P Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts)

B Moll,J García González,R Bernabe Caro,S Olson,E Arriola,J Lavara Sanz,M.R Garcia Campelo,D Perez Parente,D Isla

doi:10.1016/j.annonc.2022.07.1226

1101P Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts)

B Moll, J García González + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1226

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Roche (Spain), Complejo Hospitalario Universitario de Santiago, Hospital Universitario Virgen del Rocío, Hospital Del Mar, Instituto de Investigación Biomédica de A Coruña, Hospital Clínico Universitario Lozano Blesa

#Use Of Genomic Sequencing #Lung Cancer Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LC is the leading cause of cancer death worldwide. The accurate determination of genomic alterations can provide valuable information to find the best therapeutic approach for each pts. Thus, Foundation Medicine services were used to determine the genomic profile of Spanish LC pts with no previously identified mutations by immunohistochemistry in clinical practice.

Full Text